Clinical trials: Psoriatic-arthritis
Rheumatoid Arthritis, Ankylosing Spondylitis
Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
The purpose of this non-interventional, multicenter, post-marketing observational study (PMOS) was to assess rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PS), Crohn's…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Crohn´s Disease
- Trial name
- Adherence (NCT01768858)
- Testing
- Adalimumab
- Volunteers
- 96 people
- Sponsor
- AbbVie
Rheumatoid Arthritis, Inflammatory Bowel Disease
Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis
Purpose: With the existing biologic anti-inflammatory product patents expiring and the FDA approval of new biosimilar and innovator biologics, patients with rheumatologic (RA), psoriatic (PsO-PsA-AS), and gastrointestinal (GI)…
- Conditions
- Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis, Psoriatic Arthritis
- Trial name
- NCT02922192
- Testing
- TNF-α antagonists, non-TNFs, DMARD non-biologics
- Volunteers
- 90,360 people
- Sponsor
- Biologics & Biosimilars Collective Intelligence Consortium
Rheumatoid Arthritis, Spondyloarthritis
The NOR-SWITCH Study
The purpose of this study is to assess the safety and efficacy of switching from Remicade to the biosimilar treatment Remsima in patients with rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis…
- Conditions
- Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis, Ulcerative Colitis
- Trial name
- NOR-SWITCH (NCT02148640)
- Testing
- Innovator infliximab, Biosimilar infliximab
- Where
- 30 sites in Norway
- Volunteers
- 482 people
- Sponsor
- Diakonhjemmet Hospital
Psoriasis, Psoriatic Arthritis
Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis
Plaque Psoriasis is a chronic inflammatory disease in which skin cells build up and develop scaly red and white patches on the skin.
- Trial name
- NCT04433442
- Where
- 63 sites in South Korea
- Volunteers
- 2,324 people
- Sponsor
- AbbVie
Psoriatic Arthritis, Obesity
Small Changes Behavioural Weight Loss Treatment Approach for Psoriatic Arthritis Patients With Comorbid Obesity
Psoriatic Arthritis (PsA) is a type of auto-immune condition that affects roughly 90,000 Canadians. Patients with PsA often experience joint pain, skin problems, and issues with mobility that negatively impact their quality of…
- Trial name
- NCT05225623
- Testing
- BWLT, Waitlist Control for BWLT
- Where
- Canada
- Volunteers
- 38 people
- Sponsor
- University of Calgary
Arthritis, Psoriatic
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
The primary purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active Psoriatic Arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
- Trial name
- Discover-1 (NCT03162796)
- Testing
- Guselkumab
- Where
- 95 sites in United States, Australia and 11 more
- Volunteers
- 383 people
- Sponsor
- Janssen Research & Development, LLC
Psoriatic Arthritis
Monocyte Chemoattractant Protein-1 in Psoriatic Arthritis Patients
1. Evaluate serum levels of (MCP-1) in PsA with or without cardiovascular affaction . 2. Detect subclinical cardiovascular affaction in patients with PsA for early diagnosis and management .
- Trial name
- NCT05637905
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Assiut University
Psoriatic Arthritis
Treatment Goals in Psoriatic Arthritis
The PaGoPsA study objective is to ascertain if guideline-based psoriatic arthritis clinical care achieves individual patient goals as articulated by patients, and to identify predictors of achieving individual patient goals from…
- Trial name
- PaGoPsA (NCT03620188)
- Testing
- Standard of care
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Johns Hopkins University
Wrist Arthritis, Psoriatic Arthritis
Arthroscopic Synovectomy of the Wrist in Inflammatory Arthritis
Rationale: Psoriatic (PsA) and rheumatoid arthritis (RA) are inflammatory joint diseases that often involve the wrist and may result in progressive joint destruction followed by impaired wrist function and reduced quality of…
- Conditions
- Wrist Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Surgery
- Trial name
- ARCTIC (NCT04755127)
- Testing
- Arthroscopic synovectomy of the wrist, Intra-articular corticosteroid injection
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Maasstad Hospital
Rheumatoid Diseases, Rheumatoid Arthritis
Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade
To assess persistence of CT-P13 in patients with Rheumatoid Diseases (Rheumatoid arthritis [RA], ankylosing spondylitis [AS], and psoriatic arthritis [PsA]) who are naïve to biologics or are switching from stable Remicade to…
- Conditions
- Rheumatoid Diseases, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- PERSIST (NCT02605642)
- Testing
- CT-P13
- Where
- 38 sites in Bulgaria, Canada and 5 more
- Volunteers
- 351 people
- Sponsor
- Pfizer
Psoriatic Arthritis, Psoriasis
Ultrasound Enthesitis Response in Psoriatic Arthritis
The aim of this observational study will be to recruit 100 Psoriatic Arthritis (PsA) patients beginning on their biologic therapy and asses, both clinically and with the use of ultrasound (US), how enthesitis responds to biologic…
- Conditions
- Psoriatic Arthritis, Psoriasis, Enthesitis
- Trial name
- NCT03955861
- Testing
- adalimumab, Certolizumab, Etanercept
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- Belfast Health and Social Care Trust
Psoriatic Arthritis, Psoriasis (PsO)
Inflammation Digital Biomarkers Validation Study
HIPPOCRATES is an Innovative Medicines Initiative (IMI) funded EU Consortium established to address key unmet clinical needs in psoriatic disease.
- Trial name
- IDBV (NCT07594054)
- Volunteers
- 3,458 people
- Sponsor
- University of Oxford
Spondyloarthritis
99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis
This single center, open-label, proof of concept (PoC) Phase II study aimed to assess the investigational imaging agent 99mTc-rhAnnexin V-128 in detecting spondyloarthritis (SpA) lesions.
- Trial name
- Annexin 03 (NCT03232580)
- Testing
- rhAnnexin V-128
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Advanced Accelerator Applications
Psoriatic Arthritis
Molecular Effects of Apremilast in the Synovium of Psoriatic Arthritis Patients
This study assess the genomics profiles in synovial biopsies obtained prior to, and 24 weeks after an immunomodulator agent (Apremilast) in patients with active psoriatic arthritis who are naive to treatment with a conventional…
- Trial name
- MEAS (NCT04645420)
- Testing
- Global gene expression profiles obtained from synovial biopsies.
- Where
- Belgium
- Volunteers
- 19 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Spondylarthropathies, Ankylosing Spondylitis
TNFalfa Blocking Treatment of Spondylarthropathies
The purpose of the study is to establish a Danish cohort of spondylarthropathy (SpA) patients who are being treated with TNFalfa blockers.
- Conditions
- Spondylarthropathies, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT00133315
- Testing
- Infliximab, Etanercept, Adalimumab
- Where
- 9 sites in Denmark
- Volunteers
- 50 people
- Sponsor
- Hvidovre University Hospital
Arthritis, Psoriatic
A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy
The purpose of this study is to evaluate guselkumab efficacy versus placebo in participants with active psoriatic arthritis (PsA) and an inadequate response to Anti-Tumor Necrosis Factor Alpha (TNF-alpha) therapy by assessing the…
- Trial name
- COSMOS (NCT03796858)
- Testing
- Guselkumab 100 mg
- Where
- 117 sites in Belgium, Bulgaria and 12 more
- Volunteers
- 285 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Psoriatic Arthritis
Psoriatic Arthritis Research Collaborative: Biologic Sub-Study
Psoriatic arthritis (PsA) is an inflammatory arthritis with substantial variation in clinical features. We propose a multicenter collaborative approach to better understand the phenotypes and current management of PsA in the…
- Trial name
- PARC-B (NCT03378336)
- Where
- 4 sites in United States
- Volunteers
- 171 people
- Sponsor
- University of Pennsylvania
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Psoriatic Arthritis
Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo
To demonstrate that the efficacy of secukinumab 300 mg at Week 16 was superior to placebo in adult patients with active PsA based on the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response.
- Trial name
- NCT02798211
- Testing
- Secukinumab 300 mg, Secukinumab 150 mg
- Where
- 58 sites in United States, Puerto Rico
- Volunteers
- 258 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Arthritis, Psoriatic
Anti-Carbamylated Protein Antibodies in Psoriatic Arthritis
Anti-carbamylated protein (anti-CarP) antibodies are present in approximately one-fourth of the patients who are seronegative for both rheumatoid factor and anti-citrullinated protein antibody and who may therefore have psoriatic…
- Trial name
- CARPAPA (NCT04173039)
- Testing
- Serum anti-CarP antibodies detection
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Association pour la Recherche Clinique et Immunologique